A 16-month-long experience of COVID-19 in allogeneic haematopoietic stem cell transplantation recipients: An SFGM-TC multicentre cohort study.
Fiche publication
Date publication
mars 2023
Journal
British journal of haematology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERCEANU Ana, Pr RUBIO Marie Thérèse
Tous les auteurs :
Xhaard A, Xhaard C, Rubio MT, Berceanu A, Botella-Garcia C, Coman T, Tavernier E, Labussière-Wallet H, Chevallier P, Legrand F, Thiebaut A, Menard AL, Paillard C, Chantepie S, Robin M, Nguyen S
Lien Pubmed
Résumé
This 16-month-long multicentre retrospective study of 225 allogeneic haematopoietic stem cell transplantation (alloHSCT) recipients with COVID-19 examines risk factors for severity and mortality, describing the successive waves of infections (from March to June 2020 and from August 2020 to June 2021). We confirm the negative role of low respiratory tract disease and immunosuppressive treatment. We highlight significantly lower percentages of severe forms and COVID-19-related mortality during the second wave. Monthly comparative evolution of cases in alloHSCT recipients and in the French population shows a higher number of cases in alloHSCT recipients during the first wave and a decrease from February 2021.
Mots clés
COVID-19, SARS-CoV-2, allogeneic hematopoietic stem cell transplantation, infection
Référence
Br J Haematol. 2023 03 15;: